# ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body

> **NCT00061126** · PHASE2 · COMPLETED · sponsor: **Abgenix** · enrollment: 50 (—)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** ABX-EGF

## Key facts

- **NCT ID:** NCT00061126
- **Lead sponsor:** Abgenix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 50 (—)
- **Last updated:** 2005-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00061126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00061126, "ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00061126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*